Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
复制标题
DOI：
10.1111/j.1464-5491.2012.03698.x
复制
发表时间：
2012-07-01
影响因子：
3.5
通讯作者：
Varley, D.
中科院分区：
文献类型：
--
作者：
Hex, N.;Bartlett, C.;Varley, D.
Diabet。【摘要】目的评估英国1型和2型糖尿病当前和未来的经济负担。方法采用自顶向下的方法，从汇总的数据集和文献中估计2010/2011年的成本。患病率和人口数据用于预测2035/2036年的成本。根据诊断、生活方式干预、持续治疗和管理以及并发症的数据估计直接卫生费用。根据死亡率、疾病、出勤（仍在工作的人可能丧失的生产力）和非正式护理方面的数据估算了间接成本。结果2010/2011年，英国的糖尿病成本约为237亿英镑：直接成本为98亿英镑（1型糖尿病为10亿英镑，2型糖尿病为88亿英镑），间接成本为139亿英镑（9亿英镑和130亿英镑）。按实际价值计算，2035/2036年的成本估计为398亿英镑：直接成本为169亿英镑（1型糖尿病为18亿英镑，2型糖尿病为151亿英镑），间接成本为229亿英镑（24亿英镑和205亿英镑）。对直接成本的敏感性分析得出了一系列成本：2010/2011年为79亿英镑至117亿英镑，2035/2036年为138亿英镑至200亿英镑。糖尿病目前约占卫生资源总支出的10%，预计在2035/2036年将占17%左右。结论1型和2型糖尿病是英国的突出疾病，是一个重大的经济负担。区分1型和2型糖尿病成本的数据很少。与这些疾病有关的并发症占直接保健费用的很大一部分。随着患病率的增加，如果维持目前的护理制度，治疗并发症的费用将会增加。
Diabet. Med. 29, 855862 (2012) Abstract Aims To estimate the current and future economic burdens of Type 1 and Type 2 diabetes in the UK. Methods A top-down approach was used to estimate costs for 2010/2011 from aggregated data sets and literature. Prevalence and population data were used to project costs for 2035/2036. Direct health costs were estimated from data on diagnosis, lifestyle interventions, ongoing treatment and management, and complications. Indirect costs were estimated from data on mortality, sickness, presenteeism (potential loss of productivity among people who remain in work) and informal care. Results Diabetes cost approximately 23.7bn pound in the UK in 2010/2011: 9.8bn pound in direct costs (1bn pound for Type 1 diabetes and 8.8bn pound for Type 2 diabetes) and 13.9bn pound in indirect costs (0.9bn pound and 13bn) pound. In real terms, the 2035/2036 cost is estimated at 39.8bn pound: 16.9bn pound in direct costs (1.8bn pound for Type 1 diabetes and 15.1bn pound for Type 2 diabetes) and 22.9bn pound in indirect costs (2.4bn pound and 20.5bn) pound. Sensitivity analysis applied to the direct costs produced a range of costs: between 7.9bn pound and 11.7bn pound in 2010/2011 and between 13.8bn pound and 20bn pound in 2035/2036. Diabetes currently accounts for approximately 10% of the total health resource expenditure and is projected to account for around 17% in 2035/2036. Conclusions Type 1 and Type 2 diabetes are prominent diseases in the UK and are a significant economic burden. Data differentiating between the costs of Type 1 and Type 2 diabetes are sparse. Complications related to the diseases account for a substantial proportion of the direct health costs. As prevalence increases, the cost of treating complications will grow if current care regimes are maintained.